JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M907722199 on March 27, 2000

J. Biol. Chem., Vol. 275, Issue 29, 22324-22330, July 21, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/29/22324    most recent
M907722199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Radominska-Pandya, A.
Right arrow Articles by Nowak, G.{m. d.}y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radominska-Pandya, A.
Right arrow Articles by Nowak, G.{m. d.}y.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Direct Interaction of All-trans-retinoic Acid with Protein Kinase C (PKC)

IMPLICATIONS FOR PKC SIGNALING AND CANCER THERAPY*

Anna Radominska-PandyaDagger §, Guangping ChenDagger , Piotr J. CzernikDagger , Joanna M. LittleDagger , Victor M. Samokyszyn, Charleata A. Carter||, and Graz·yna Nowak**

From the Departments of Dagger  Biochemistry and Molecular Biology, Pharmacology,  Toxicology, || Obstetrics and Gynecology, and ** Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205

Received for publication, September 20, 1999, and in revised form, March 14, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Protein kinase C (PKC) regulates fundamental cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis. All-trans-retinoic acid (atRA) modulates PKC activity, but the mechanism of this regulation is unknown. Amino acid alignments and crystal structure analysis of retinoic acid (RA)-binding proteins revealed a putative atRA-binding motif in PKC, suggesting existence of an atRA binding site on the PKC molecule. This was supported by photolabeling studies showing concentration- and UV-dependent photoincorporation of [3H]atRA into PKCalpha , which was effectively protected by 4-OH-atRA, 9-cis-RA, and atRA glucuronide, but not by retinol. Photoaffinity labeling demonstrated strong competition between atRA and phosphatidylserine (PS) for binding to PKCalpha , a slight competition with phorbol-12-myristate-13-acetate, and none with diacylglycerol, fatty acids, or Ca2+. At pharmacological concentrations (10 µM), atRA decreased PKCalpha activity through the competition with PS but not phorbol-12-myristate-13-acetate, diacylglycerol, or Ca2+. These results let us hypothesize that in vivo, pharmacological concentrations of atRA may hamper binding of PS to PKCalpha and prevent PKCalpha activation. Thus, this study provides the first evidence for direct binding of atRA to PKC isozymes and suggests the existence of a general mechanism for regulation of PKC activity during exposure to retinoids, as in retinoid-based cancer therapy.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Protein kinase C (PKC)1 is from a gene family of serine/threonine protein kinases that are key regulatory enzymes in signal transduction. The PKC family consists of several subfamilies (classic: alpha , beta I, beta II, gamma ; novel: delta , epsilon , theta , eta ; atypical: lambda , zeta , iota ) classified according to their requirements for Ca2+, phospholipids (phosphatidylserine (PS)) and diacylglycerol (DAG) or phorbol esters for activation (1-4). The classic and novel PKC isozymes contain an amino-terminal regulatory domain and a carboxyl-terminal catalytic domain (4). The regulatory domain of classic PKC isozymes contains two common regions, C1 and C2. The C1 domain mediates DAG and phorbol ester binding through distinct low and high affinity binding sites (5), while the C2 domain mediates Ca2+ and PS binding and contains the receptor for activated C kinase binding site (6, 7). PKC requires acidic phospholipids for its activity, and, in the presence of activators, the enzyme has the highest binding affinity for membranes containing PS. Upon activation, PKC isozymes are translocated to distinct subcellular compartments (membranes) and cell structures to phosphorylate their respective substrates (4, 8). This compartmentalization is required for the phosphorylation of specific substrates and the regulation of different physiological functions (4, 9). Preventing PKC translocation from the cytoplasm to membranes inhibits PKC function and the subsequent phosphorylation of specific substrates (7, 9).

PKC isozymes regulate gene expression and a variety of cellular functions, including growth, differentiation, tumor promotion, aging, and apoptosis (1, 2, 5); however, the biological significance of the heterogeneity in the PKC family is not clear. The distinct subcellular distribution, the presence of several isozymes in the same cell, and differential activation or inhibition by different stimuli suggest that each isozyme is involved in the regulation of different functions and has a unique role in the cell (2, 4, 9, 10).

Retinoids are vitamin A derivatives that regulate cellular growth, differentiation, development, and apoptosis (11, 12). Retinoids control gene expression and synthesis of a variety of proteins through nuclear retinoic acid receptors and are directly involved in regulation of numerous signaling molecules, including PKC (13-18). Specifically, retinoids have been implicated in the mechanism of reversion from the malignant to the normal cell phenotype, inhibition of cancer invasiveness, and are currently used to treat various types of cancer, including promyelocytic leukemia, head and neck, skin, breast, and ovarian cancers (19-22). It has been postulated that retinoids exert some of their effects on cellular differentiation and reversion of malignant phenotype through interactions with PKC isozymes (13, 16, 23, 24). It has been shown that retinoic acid alters the cellular localization of PKCalpha , consistent with PKCalpha inactivation, in endometrial adenocarcinoma cells concurrent with the induction of differentiation of these cells (24). Collectively, the data suggest that alterations in PKC activity induced by retinoids are associated with reversion of the malignant phenotype (25-27). However, the mechanism by which retinoic acid regulates PKC is not known.

In this work, we have begun the characterization of the biochemical events underlying this regulation. We have previously identified an amino acid motif common to the putative RA binding sites of several RA-utilizing proteins (28). The presence of this motif in several PKC isoforms led us to postulate and examine the existence of cellular mechanisms that mediate receptor-independent signaling by retinoids through a direct interaction with various PKC isozymes. We have used photoaffinity labeling to demonstrate that purified, recombinant PKCs bind atRA with high affinity. Using PKC activity assays, we have shown that preincubation of PKCalpha with micromolar concentrations of atRA decreases PKC activity.

Taken together, this is the first evidence for a direct, high affinity binding of atRA to PKCalpha that results in a decrease in PKCalpha activity. Given the significance of these in vitro results, we hypothesize that atRA might also be involved in regulating PKCalpha activity in vivo by competing with PS for binding to PKC molecules. The exact localization of the atRA binding sites is under investigation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Materials

Recombinant human PKC isoforms and catalytic subunit were obtained from Calbiochem (La Jolla, CA). All-trans-retinoic acid (atRA), phosphatidyl-L-serine (PS), phorbol 12-myristate 13-acetate (PMA), histone type III, diacylglycerol (DAG, 1,2-dioctanoyl-sn-glycerol), and arachidonic acid (AA) were from Sigma. [11,12-3H]All-trans-retinoic acid ([3H]atRA) was purchased from NEN Life Science Products, and adenosine 5'-[gamma -32P]triphosphate ([gamma -32P]ATP) was from Amersham Pharmacia Biotech. NuPAGE 4-12% BisTris gels, sample buffer, and running buffer were from Novex (San Diego, CA). All other reagents were of the highest purity available.

Methods

Amino Acid Alignment Polypeptides for CRABP I (29), CRABP II (29), and RAR (30) were selected on the basis of the crystal structures of these proteins with atRA bound. A polypeptide for UGT2B7 was selected according to modeling of a RA binding site in this protein (28). Polypeptides for PKC proteins were chosen through a homology comparison to CRABP and RARgamma proteins and represent COOH-terminal fragments of their C2 domains. Sequences were aligned using programs resident in the GCG Protein and DNA Analysis Package (31).

Photoaffinity Labeling with [3H]atRA Direct photoaffinity labeling with [3H]atRA was done using modifications of the method described by Bernstein (32). For screening of the different PKC isoforms, 7 pmol each of PKCalpha , beta I, beta II, gamma , delta , epsilon , and zeta  in 20 mM HEPES, pH 7, were incubated for 2 min at room temperature with or without 30 µM atRA. The PKC catalytic subunit was labeled according to the same protocol, except that only 2 pmol of protein was used. [3H]atRA (30 Ci/mmol) was added to a final concentration of 1.5 µM (0.03 nmol, ~1 µCi, in a final volume of 20 µl). atRA and [3H]atRA were added in ethanol with a final concentration of 2% ethanol in all samples. Samples were incubated for 10 min on ice prior to photolabeling with a handheld long wave (366 nm) UV lamp (UVP-21, Ultraviolet Products, San Gabriel, CA) for 15 min. Proteins were denatured by addition of NuPAGE denaturing buffer (Novex) followed by sonication, boiling for 1 min and, finally, centrifugation at 13,000 rpm in an Eppendorf microcentrifuge (Brinkman Instruments, Westbury, NY). Proteins were separated by SDS-polyacrylamide gel electrophoresis on a NuPAGE minigel (1.5 mm).

Following electrophoresis, gels were stained with Coomassie Blue, destained, washed thoroughly with water, treated with Autofluor autoradiography enhancer, (National Diagnostics, Manville, NJ), dried, and subjected to autoradiography at -80 °C for 4-7 days. Results were quantitated by densitometric analysis of the autoradiograms using an AlphaInnotech IS-1000 Digital Imaging System (AlphaInnotech, San Leandro, CA).

For more detailed studies with PKCalpha , photoaffinity labeling was carried out in essentially the same manner using 0.2 µg (2.6 pmol) of protein/sample in a final volume of 10 µl with an ethanol concentration of 5%. Any other modifications are given in the descriptions of specific experiments.

Enzymatic Assay

Preparation of Mixed Micelles-- PS (2.8 mg) and PMA (final concentration: 100 µM) dissolved in chloroform were transferred to a glass tube. Following evaporation of chloroform under a stream of nitrogen, 1 ml of 3% Triton X-100 (prepared fresh) was added and the mixture was sonicated.

PKC Assay-- PKCalpha activity was assayed with Triton X-100 mixed micelles, using the phosphorylation of histone 1, as described by Bell et al. (33). Unless stated otherwise, the reaction mixture contained 20 mM Tris (pH 7.5), 20 mM MgCl2, 1.0 mM CaCl2, 0.25 mM EGTA, 0.25 mM EDTA, 0.28 mg/ml PS, 10 µM PMA, 1 mM beta -mercaptoethanol, 0.3% Triton X-100, 50 µM histone 1, 20 µM [gamma -32P]ATP, and 150 milliunits of PKCalpha in a final volume of 25 µl. Samples were incubated for 5 min at 30 °C, and reactions were terminated by spotting an aliquot of reaction mixture on phosphocellulose disks (P-81, 2.3 cm, Whatman, Clifton, NJ). After washing the disks with 1% phosphoric acid, gamma -32P incorporation into histone 1 was determined by liquid scintillation spectrometry. Non-PKCalpha -specific activity (background) was determined in samples incubated in the absence of the enzyme.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Amino Acid Alignment-- Amino acid alignments and comparison of the crystal structures of several atRA-utilizing proteins, such as CRABP I and II (cytosolic retinoic acid-binding protein I and II), nuclear receptor RARgamma and UGT2B7 (the enzyme catalyzing glucuronidation of atRA) with the C2 domain of PKC was carried out as the initial step in the investigation. A motif, previously designated as comprising part of the atRA-binding site, was present in three PKC isozymes examined (alpha , beta I, and gamma ) (Fig. 1).


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 1.   Comparison of amino acid alignments of the C2 domain for PKC and various proteins that interact with atRA. Amino acids conserved in CRABP and UGT2B7 (yellow blocks), conserved in PKCs and RARgamma (green blocks), and maintained across all the analyzed sequences (red blocks) are shown. For the purpose of this alignment, amino acids in the hydrophobic set (Leu, Val, Ile, Ala), the hydrophilic set (Thr, Ser, Asn), the acidic set (Asp, Glu), and the basic set (Lys, Arg, His) were considered homologous.

The amino acid distribution among the analyzed sequences revealed three categories of homologous amino acids (Fig. 1): conserved in CRABP and UGT2B7 (yellow blocks), conserved in PKCs and RARgamma (green blocks), and those maintained across all the analyzed sequences (red blocks). For the purpose of this alignment, amino acids in hydrophobic set (Leu, Val, Ile, Ala), hydrophilic set (Thr, Ser, Asn), acidic set (Asp, Glu) and basic set (Lys, Arg, His) were considered homologous. The alignment shows a significant homology of amino acids in the C2 domains to amino acids constituting RA binding pockets for CRABPs, RARgamma , and that predicted for UGT2B7 (double underlined sequences). Arg-249 of PKCalpha and PKCgamma corresponds to Arg-111 involved in the interaction with the RA carboxyl in CRABPs and Lys-229 of RARgamma , involved in electrostatic interaction with the ligand (star). A lysine cluster that constitutes a phosphatidylserine binding site in C2 domains is positioned 35 amino acids upstream from the center of the predicted RA binding site of PKCs.

On the basis of the significant sequence homologies among the analyzed sequences, we propose that the amino acids shown on the consensus line might represent all or part of the RA binding pocket of PKCalpha . The conserved motif in CRABP I contains five amino acids, Arg-111, Leu-120, Phe-122, Arg-131, and Tyr-133, which have been identified from analysis of the crystal structure as being a part of the atRA binding pocket (29, 34).

Additionally, significant homologies between a PKCalpha sequence pattern containing the previously defined PS binding site and the predicted atRA binding site (amino acids 172-260) of the C2 domain and the PKCzeta C1 domain sequence were not detected.

Photoaffinity Labeling-- To test our hypothesis of a direct interaction between atRA and PKC, we used direct photoaffinity labeling of PKCalpha with [11,12-3H]atRA, which covalently modified the PKCalpha protein within the atRA-binding site and provided the direct evidence for atRA binding to PKC. Because atRA is one of the several common retinoids used experimentally and clinically, it was the retinoid of choice to investigate the direct interaction between retinoids and PKC. The photoaffinity labeling occurred in a concentration-dependent manner, was dependent on UV irradiation, and was effectively protected by unlabeled atRA, atRA glucuronide (atRAG), and various other retinoids (Fig. 2). It has been demonstrated here that PKCalpha exhibits different affinities for various retinoids and that the presence of a carboxyl function on the ligand was an obligatory requirement for binding to PKC. All RA derivatives tested, with the exception of 13-cis-RA, strongly inhibited binding of atRA to PKCalpha . These results also indicate that atRA derivatives such as 9-cis-RA and atRAG might be functional ligands for PKCalpha . Thus, our data demonstrate that atRA binds to PKCalpha through a RA-binding site and that this process is highly specific.


View larger version (48K):
[in this window]
[in a new window]
  		Fig. 2.   Photoaffinity labeling of PKCalpha by [3H]atRA and protection with various retinoids. Direct photoaffinity labeling with [3H]atRA carried out as described under "Experimental Procedures." A, PKCalpha was photolabeled with different concentrations of [3H]atRA. Lane 1, control with no UV; lanes 2-7, increasing concentrations of [3H]atRA (0.4125, 0.825, 1.65, 3.3, 6.6, and 13.2 µM). The graph is a plot of relative density versus concentration of [3H]atRA ligand, demonstrating the concentration dependence of photoincorporation of [3H]atRA. B, protection of PKCalpha from photolabeling with unlabeled atRA, atRAG, retinol, 9-cis-RA, 13-cis-RA, and 4-OH-atRA. For each ligand, lanes 1-4 represent increasing concentrations of retinoid (0, 5, 25, and 125 µM). The graphs show the results of quantitation of the protection experiments by densitometry.

To characterize atRA interactions with PKC, we examined the ability of atRA to compete with different PKC activators such as PS, PMA, DAG, and Ca2+ for binding to PKCalpha . Fig. 3 showed that there was a strong competition between PS and atRA for binding to PKCalpha but only a slight competition between PMA and atRA and no competition between DAG and atRA. These results indicated that atRA does not interact with PKCalpha through the PMA or DAG binding sites. They also confirmed that atRA binds specifically to PKCalpha and competes with PS for binding. This is consistent with our hypothesis based on the amino acid analysis shown in Fig. 1 and with a model proposing that PS interacts with PKC within a different domain than DAG and PMA. Calcium had no effect on atRA binding to PKCalpha in the presence of PS, PMA, or DAG (data not shown), which demonstrates that, although PS and Ca2+ binding sites are localized to the same domain (C2) of PKCalpha , atRA does not interact with PKCalpha through the Ca2+ binding site (Fig. 3).


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 3.   Photoaffinity labeling of PKCalpha by [3H]atRA and protection with various activators of PKC. PKCalpha was photolabeled with [3H]atRA and protected by various activators of PKC (PS, PMA, and DAG). Four lanes are shown for each ligand, representing increasing concentrations of activator (0, 25, 50, and 250 µM).

In order to identify whether other PKC isozymes contain atRA-binding sites, PKCalpha , beta I, beta II, gamma , delta , epsilon , and zeta  were photolabeled under the same conditions with equimolar concentrations of PKC protein and the ligand. The data presented in Fig. 4 show that all PKC isozymes investigated were photolabeled; however, clear differences in the degree of incorporation of label into individual isozymes were observed. Thus, PKCbeta II had the highest affinity for atRA, while PKCzeta had the lowest affinity.


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 4.   Differential photoaffinity labeling of PKC isoforms by [3H]atRA. Seven different isoforms (alpha , beta I, beta II, gamma , delta , epsilon , and zeta ) of PKC were photolabeled with 3.3 µM [3H]atRA. The photoaffinity labeling was performed as described above. The relative photoincorporation of [3H]atRA into the PKC isoforms was determined by densitometry. PKCbeta II showed the highest photoincorporation of [3H]atRA; therefore, it was assigned a density of 100%, and all other densities are expressed as percentages of PKCbeta II activity.

The catalytic subunit of PKC was used for photoaffinity labeling to determine other possible sites of atRA binding to the PKC molecule. There was some atRA binding to the catalytic subunit of PKC (~3% of atRA binding to PKCalpha ). However, this binding was not UV-light dependent nor was it protected by unlabeled atRA (data not shown). These results indicated that there is no specific interaction between atRA and the PKC catalytic subunit and suggested that atRA binding occurs in the regulatory subunit of PKC. However, the efficiency of this binding differs depending on the PKC isoform being used for photolabeling.

Direct comparison of the photolabeling of PKCalpha and PKCzeta by atRA and protection by PS and arachidonic acid were also carried out and the data are presented in Fig. 5. PKCzeta was photolabeled by atRA with 6-fold lower efficiency than PKCalpha . Like photolabeling of PKCalpha , the photolabeling of PKCzeta by atRA was light-sensitive and protected by increasing concentrations of unlabeled atRA, which demonstrated that atRA binding to PKCzeta is specific. However, in contrast to PKCalpha , the photolabeling of PKCzeta was not protected by preincubation with PS (Fig. 5). Furthermore, there was no competition between arachidonic acid and atRA for binding to PKCalpha , but the photolabeling of PKCzeta by atRA was dramatically diminished by all concentrations of arachidonic acid used in the study (Fig. 5). No effect of PMA on PKCzeta photolabeling by atRA was found (data not shown).


View larger version (49K):
[in this window]
[in a new window]
  		Fig. 5.   Photoaffinity labeling of PKCalpha and PKCzeta by [3H]atRA and protection by unlabeled atRA, PS, and A. PKCalpha and PKCzeta were photolabeled with [3H]atRA in the absence and presence of increasing concentrations (0, 5, 25, and 125 µM) of unlabeled atRA (lanes 2-5), PS (lanes 6-9), or AA (lanes 10-13); lane 1, no UV.

Taken together, these data suggest that: 1) the majority of atRA binds to the regulatory subunit of PKC and 2) the major atRA binding site in PKCalpha may be localized in close proximity to the PS binding site. These results also show that there is no apparent affinity of atRA for the fatty acid binding site of PKCalpha , presumably localized to the C1 domain. In the case of PKCzeta , which lacks the C2 domain and is strongly regulated by fatty acids (35), atRA may bind to the C1 domain either in, or in close proximity to, the fatty acid binding site.

Recent site-directed mutagenesis studies from another laboratory carried out on several residues in the C2 domain of PKCalpha , including the arginine residues, Arg-249 and Arg-252, indicated that all mutants exhibited full membrane binding affinity and enzymatic activity at saturating concentrations of PS, DAG, and Ca2+ (43). These studies also have shown that amino acids Arg-249 and Arg-252 in the C2 domain of PKCalpha are involved in electrostatic interactions with membrane anionic phospholipids. The two arginines are positioned in the center of our amino acid alignment of proteins that bind RA (Fig. 1), with Arg-249 being highly conserved. Particularly, Arg-249 aligns with Arg-111 of CRABP I and II, which is involved in electrostatic interaction with carboxyl function of RA (29). It is likely that RA may interact with Arg-249 and/or Arg-252 of PKC in a similar fashion and, thus, could be responsible for the interplay between PS and RA demonstrated in our studies. This explanation does not exclude other possible interpretations for RA-mediated modifications of PKC activity, including a RA-induced allosteric effect.

The general conclusion from these experiments is that all the PKC isoforms studied directly interact with atRA but the binding of atRA to different isoforms occurs with different affinity. Although the major site of atRA binding in PKCalpha is postulated to be on the regulatory domain, in PKCzeta , the binding occurs in the C1 domain of the regulatory subunit. The exact location and the nature of this binding and its relation to PS and arachidonic acid binding are currently under investigation in our laboratory. Whether the interaction between PKC and RA results in up- or down-regulation of PKC activity clearly depends on the biological system being studied (36, 37).

Enzymatic Activity-- To examine the effects of atRA binding on PKC catalytic activity, the activity of purified PKCalpha , the most common PKC isoform, was determined in the presence or absence of atRA and various PKC activators. Pre-incubation of PKCalpha with PS and PMA, followed by the addition of increasing concentrations of atRA, resulted in a 23% and 61% decrease in PKCalpha activity in the presence of 50 and 100 µM atRA, respectively (Fig. 6; data not shown for 100 µM). At concentrations lower than 50 µM, atRA had no effect if added following pre-incubation with the PS/PMA complex. Simultaneous incubation of PKCalpha with PS, PMA, and atRA resulted in a slight (20%) decrease in PKCalpha activity in the presence of 1-10 µM atRA and a 30% decrease in PKCalpha activity in the presence of 20-50 µM atRA (Fig. 6). In contrast, pre-incubation of PKCalpha with atRA prior to addition of the PS/PMA complex resulted in a dramatic decrease in PKCalpha activity (40% and 62% in the presence of 1 and 20 µM atRA, respectively) and total inhibition of the kinase activity at 50 µM atRA (Fig. 6). These results show that: 1) atRA decreases PKCalpha activity, 2) atRA competes with PS and/or PMA for binding to PKCalpha , and 3) atRA binds to PKCalpha with a high affinity and cannot be displaced by an addition of PS and/or PMA.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 6.   Effect of atRA on PKCalpha activity. In general, PKCalpha activity was assayed as described under "Experimental Procedures," and details are provided with individual experiments. To assess the overall effect of atRA on PKC activity, prior to the measurement of enzymatic activity, PKCalpha was incubated at 30 °C in the presence of 1) mixed micelles containing Triton X-100, PS, PMA and increasing concentrations of atRA for 10 min (PS/PMA/atRA + PKC); 2) mixed micelles containing Triton X-100, PS, and PMA for 10 min followed by 10 min of incubation in the presence of increasing concentrations of atRA (PS/PMA + PKC + atRA); or 3) increasing concentrations of atRA for 10 min followed by 10 min of incubation in the presence of mixed micelles containing Triton X-100, PS, and PMA (atRA + PKC + PS/PMA). Specific activity of PKCalpha in the presence of PS, PMA, and Ca2+ and the absence of atRA was 733 ± 78 nmol phosphate/min/ng protein. The results are expressed as % of PKC activity in the absence of atRA and presence of the vehicle (ethanol, 2% final concentration); mean ± S.E. (n = 3).

To characterize specific interactions of atRA with individual activators of PKCalpha , the enzyme was pre-incubated in the presence of 20 µM atRA or the vehicle and the activity measured following addition of increasing concentrations of PS, PMA, DAG, and Ca2+. In the absence of atRA, PKCalpha activity was stimulated by PS in a concentration-dependent manner and reached a plateau at concentration of 350 µg/ml PS (23-fold stimulation in comparison with PKCalpha activity in the absence of PS) (Fig. 7). In the presence of atRA, the stimulation of PKCalpha activity by PS was decreased to 30% of the stimulation in the absence of atRA. These results show that atRA decreases stimulation of PKCalpha activity by PS and suggest that atRA and PS compete for binding to PKCalpha .


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 7.   Effect of PS on PKCalpha activity in the presence and absence of atRA. Prior to measurement of PKCalpha activity, the enzyme was incubated for 10 min at 30 °C in the presence of ethanol or 20 µM atRA in ethanol (2% final concentration), followed by 10 min of incubation with mixed micelles containing 0.3% Triton X-100, 10 µM PMA, and increasing concentrations of PS. The results are expressed as mean ± S.E. (n = 3).

In the absence of atRA, PKCalpha activity increased gradually in the presence of increasing concentrations of PMA and reached a plateau at a concentration of 1 µM PMA (10-fold stimulation in comparison with PKCalpha activity in the absence of PMA) (Fig. 8A). atRA decreased the activity of PKCalpha by 44% in the absence of PMA but did not prevent subsequent stimulation of the PKCalpha activity by increasing concentrations of PMA (Fig. 8A). Likewise, atRA decreased PKCalpha activity in the absence of DAG but did not prevent PKCalpha stimulation by increasing concentrations of DAG (Fig. 8B). These results show that atRA does not inhibit the activation of PKCalpha by PMA or DAG and suggest that atRA does not compete with PMA or DAG for binding. Finally, atRA decreased the overall PKCalpha activity by 53% in the absence of Ca2+ and the presence of PS and PMA but did not prevent PKCalpha stimulation by increasing concentrations of Ca2+ (Fig. 9). These results demonstrate that atRA prevents the stimulation of PKCalpha activity by PS and suggest that atRA alters the interaction of PS with PKCalpha .


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 8.   Effect of PMA (A) and DAG (B) on PKCalpha activity in the presence and absence of atRA. Prior to measurement of PKCalpha activity, the enzyme was incubated for 10 min at 30 °C in the presence of ethanol or 20 µM atRA in ethanol (2% final concentration), followed by 10 min of incubation with mixed micelles containing 0.3% Triton X-100, 280 µg/ml PS, and increasing concentrations of PMA or DAG. The results are expressed as mean ± S.E. (n = 3).


View larger version (14K):
[in this window]
[in a new window]
  		Fig. 9.   Effect of Ca2+ concentration on PKCalpha activity in the presence and absence of atRA. Prior to measurement of PKCalpha activity, the enzyme was incubated for 10 min at 30 °C in the presence of ethanol or 20 µM atRA in ethanol (2% final concentration), followed by 10 min of incubation with mixed micelles containing 0.3% Triton X-100, 10 µM PMA, and 280 µg/ml PS. The reaction was initiated by addition of the substrate, [gamma -32P]ATP and increasing concentrations of Ca2+. The results are expressed as mean ± S.E. (n = 3).

A Model for PKC/atRA Interaction-- A model for the proposed regulation of PKC by phosphorylation, membrane binding, and activation is well established and has been published previously (8). In this model, newly synthesized PKC associates with the detergent-insoluble fraction of cells. Three phosphorylation events convert PKC into a mature form that is released into cytosol but is inactive due to the presence of pseudosubstrate in the substrate-binding cavity. PKC translocation to the membrane occurs once DAG binds to the C1 domain and is followed by phospholipid (PS) binding to the C2 domain. Association of DAG with its binding site in the C1 domain and PS with its binding site on the C2 domain leads to pseudosubstrate release and PKC activation.

Based on our results, we propose a modification of this existing model, which accounts for the direct interaction between atRA and PKCalpha in the cell (Fig. 10). The central hypothesis of our model is that atRA binds to PKC at pharmacological concentrations (1.0 µM or higher), a situation that can result from consumption of large amounts of vitamin A or its metabolic precursors or atRA therapy (38). Under normal conditions, atRA and 13-cis-RA are present in the plasma at nanomolar concentrations (39, 40) and atRA is considered the most prevalent form of vitamin A in most tissues (41, 42). We tested our hypothesis by exploring the effect of different atRA concentrations on both atRA binding and PKC activity. The results show that, in an in vitro system, atRA binds to PKC with high affinity at concentrations above 10 µM.


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 10.   Model for the regulation of PKC by atRA and postulated involvement of CRABP proteins. The top portion of the diagram represents the release of PKC into the cytoplasm, phosphorylation of the catalytic domain (dotted oval) and optional transfer of RA from the RA/CRABP complex. The left bottom portion shows activation of PKC through interaction of the C1 domain (green circle) with DAG and the C2 domain (yellow oval) with PS, in the absence of RA binding. The scheme on the bottom right shows inhibition of the PKC activation by binding of RA, restricting the PS interaction with its binding site, and, in consequence, blocking release of the pseudosubstrate (blue rectangle). In our model, we depicted a RA molecule bound within the PS binding region. This indicates a functional relation between RA and PS but does not necessarily define the exact binding site for RA.

Because atRA does not exist in the cell in the free form, we hypothesize that it can react with PKC following binding to CRABP in those cells where PKC and CRABP are both expressed. In preliminary experiments (data not shown) on CRABP and PKC interactions, a significant decrease of CRABP photolabeling by atRA was seen in the presence of PKC, which suggests that there is an interplay between PKC, CRABP and atRA. Experiments are in progress to elucidate the exact mechanism of this interaction and its implications. Previously, it has been shown that apo-CRABP can be phosphorylated by Ca2+- and PS-dependent PKC and that holo-CRABP inhibits PKC activity (36, 44), which suggests that an interaction between RA-binding proteins and PKC may play a role in the regulation of PKC activity and retinoid action.

Our model is restricted to the regulation of PKCalpha by atRA and is still hypothetical. We propose that atRA interacts with PKC when the atRA concentration in the cell exceeds 1.0 µM (pharmacological). Following atRA entry into the cell and binding to CRABP, the complex can react with PKC. As shown in Fig. 10, the interaction of atRA and PKC may occur: 1) when PKC is associated with the detergent-insoluble fraction of cells, 2) following PKC phosphorylation and release into the cytosol, or 3) when PKC translocates to the membrane domain but prior to PKC binding to phospholipids (PS). With atRA bound to the PKCalpha molecule, the final activation by PS cannot occur. A similar model for PKCzeta is under investigation.

Our results show that, in vitro, at concentrations lower than 50 µM, atRA can not displace PS from its binding site (Fig. 6). Therefore, atRA binding to PKCalpha probably does not occur following PKC translocation to cellular membranes because the binding site is not accessible in this situation. However, once atRA is bound to PKC prior to PKC translocation, the association of PKC with membrane phospholipids and final activation cannot occur. Our examination of the crystal structure of the C2 domain of PKCalpha showed that a polypeptide of the predicted atRA binding site and a lysine cluster, which constitutes the PS binding site (45), appear to form a shared binding pocket (Fig. 11). A 23-amino acid spacer runs between and behind the two sites, bringing them to this common interface. Whether there are other atRA binding sites on the PKC molecule and the specificity of atRA binding to these sites are subjects currently being investigated.


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 11.   Distribution of binding sites for PS and RA in the C2 domain of PKCalpha . The PS binding site is marked in green, and the proposed RA binding site is marked in red; the terminal amino acids for the C2 domain polypeptide used in crystallography are underlined.

Conclusions-- Our results from PKC photoaffinity labeling and measurements of catalytic activity of PKCalpha are consistent and demonstrate: 1) the existence of a specific atRA-binding site on PKC and 2) a direct interaction between atRA and PKCalpha that decreases PKC activity. The results presented here also suggest that atRA may be involved in the mechanism of regulation of PKC activity in the cell. Previous reports are inconsistent and atRA has been shown to stimulate or inhibit PKC activity depending on the experimental model used (36, 44, 46). Cope and co-workers (47) have demonstrated an interaction, similar to that shown here, between RA and PKC in vivo in the mouse brain. The precise mechanism of the PS-atRA interaction, such as allosteric effects and/or steric hindrance to PS binding, resulting in a decrease in enzymatic activity has not been unambiguously determined.

The fact that atRA treatment modulates PKC activity could account for some of the diverse effects that atRA treatment has on cancer cells. Using retinoids at therapeutic doses to alter PKC activity could control major cellular processes in malignant cells, including inhibition of cell proliferation and initiation of differentiation or apoptosis. Thus, agents that decrease the activity of certain PKC isozymes might be beneficial as pharmacological tools to alter cellular functions regulated by these PKC isozymes, specifically under pathological conditions such as cancer.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants DK51791 and DK49715 (to A. R.-P.) and ES06765 (to V. M. S.) and by an intramural pilot grant (to C. A. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 516, Little Rock, AR 72205. Tel.: 501-686-5414; Fax: 501-603-1146; E-mail: RadominskaAnna@exchange.uams.edu.

Published, JBC Papers in Press, March 27, 2000, DOI 10.1074/jbc.M907722199

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; RA, retinoic acid; atRA, all-trans-retinoic acid; PS, phosphatidylserine; DAG, diacylglycerol (1,2-dioctanoyl-sn-glycerol); PMA, phorbol 12-myristate-13-acetate; AA, arachidonic acid; CRABP, cellular retinoic acid-binding protein; RARgamma , nuclear retinoic acid receptor gamma ; UGT, UDP-glucuronosyltransferase; atRAG, all-trans-retinoyl-beta -glucuronide; 4-OH-atRA, 4-hydroxy-atRA; BisTris, bis(2-hydroxyethyl)iminotris(hydroxymethyl) methane.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Nishizuka, Y. (1986) Science 233, 305-312
2. Nishizuka, Y. (1988) Nature 334, 661-665
3. Nishizuka, Y. (1989) JAMA 262, 1826-1833
4. Nishizuka, Y. (1988) Biofactors 1, 17-20
5. Newton, A. C. (1997) Curr. Opin. Cell Biol. 9, 161-167
6. Perin, M. S., Fried, V. A., Mignery, G. A., Jahn, R., and Sudhof, T. C. (1990) Nature 345, 260-263
7. Ron, D., Luo, J., and Mochly-Rosen, D. (1995) J. Biol. Chem. 270, 24180-24187
8. Newton, A. C. (1995) J. Biol. Chem. 270, 28495-28498
9. Mochly-Rosen, D. (1995) Science 268, 247-251
10. Mischak, H., Pierce, J. H., Goodnight, J., Kazanietz, M. G., Blumberg, P. M., and Mushinski, J. F. (1993) J. Biol. Chem. 268, 20110-20115
11. De Luca, L. M. (1991) FASEB J. 5, 2924-2933
12. Gudas, L. J. (1994) J. Biol. Chem. 269, 15399-15402
13. Isakov, N. (1988) Cell Immunol. 115, 288-298
14. Chambon, P. (1994) Semin. Cell Biol. 5, 115-125
15. Hendrix, M. J., Wood, W. R., Seftor, E. A., Lotan, D., Nakajima, M., Misiorowski, R. L., Seftor, R. E., Stetler-Stevenson, W. G., Bevacqua, S. J., and Liotta, L. A. (1990) Cancer Res. 46, 4121-4130
16. Fontana, J. A., Reppucci, A., Durham, J. P., and Miranda, D. (1986) Cancer Res. 46, 2468-2473
17. Srivastava, R. K., Srivastava, A. R., Cho-Chung, Y. S., and Longo, D. L. (1999) Oncogene 18, 1755-1763
18. Hsu, S. L., Chen, M. C., Chou, Y. H., Hwang, G. Y., and Yin, S. C. (1999) Exp. Cell Res. 248, 87-96
19. Bracke, M. E., Van Larebeke, N. A., Vyncke, B. M., and Mareel, M. M. (1991) Br. J. Cancer 63, 867-872
20. Dulaney, A. M., and Murgatroyd, R. J. (1993) Ann. Pharmacother. 27, 211-214
21. Muindi, J. R., Frankel, S. R., Huselton, C., DeGrazia, F., Garland, W. A., Young, C. W., and Warrell, R. P., Jr. (1992) Cancer Res. 52, 2138-2142
22. Lotan, R. (1996) FASEB J. 10, 1031-1039
23. Cho, Y., Tighe, A. P., and Talmage, D. A. (1997) J. Cell. Physiol. 172, 306-313
24. Carter, C. A., Parham, G. P., and Chambers, T. (1998) Pathobiology 66, 284-292
25. Tonini, G., Parodi, M., Di Martino, D., and Varesio, L. (1991) FEBS Lett. 280, 221-224
26. Kahl-Ranier, P., and Marian, B. (1994) Nutr. Cancer 21, 157-168
27. Gruber, J. R., Ohno, S., and Niles, R. M. (1992) J. Biol. Chem. 267, 13356-13360
28. Radominska-Pandya, A., Czernik, P., Little, J. M., Battaglia, E., and Mackenzie, P. I. (1999) Drug Metab. Rev. 31, 817-900
29. Kleywegt, G. J., Bergfors, T., Senn, H., Le Motte, P., Gsell, B., Shudo, K., and Jones, T. A. (1994) Structure 2, 1241-1258
30. Renaud, J. P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., and Moras, D. (1995) Nature 378, 681-689
31. Genetics Computer Group, Wisconsin Package Version 10 (0), Genetics Computer Group, Madison, WI
32. Bernstein, P. S., Choi, S. Y., Ho, Y. C., and Rando, R. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 654-658
33. Bell, R. M., Hannun, Y., and Loomis, C. (1986) Methods Enzymol. 124, 353-359
34. Thompson, J. R., Bratt, J. M., and Banaszak, L. J. (1995) J. Mol. Biol. 252, 433-446
35. Kochs, G., Hummel, R., Meyer, D., Hug, H., Marme, D., and Sarre, T. F. (1993) Eur. J. Biochem. 216, 597-606
36. Cope, F. O., Staller, J. M., Mahsem, R. A., and Boutwell, R. K. (1984) Biochem. Biophys. Res. Commun. 120, 593-601
37. Ninomiya, M., Fujiki, H., Paik, N. S., Horiuchi, T., and Boutwell, R. K. (1986) Biochem. Biophys. Res. Commun. 138, 330-334
38. Budd, G. T., Adamson, P. C., Gupta, M., Homayoun, P., Sandstrom, S. K., Murphy, R. F., McLain, D., Tuason, L., Peereboom, G., and Ganapathi, R. D. (1988) Clin. Cancer Res. 4, 635-642
39. De Luca, L. M., Darwiche, N., Celli, G., Kosa, K., Jones, C., and Ross, S. (1994) Nutr. Rev. 52, 45-52
40. Athar, M., Agrawal, R., Wang, Z. Y., Lloyd, J. R., Vickers, D. R., and Mukhtar, H. (1991) Carcinogenesis 12, 2325-2329
41. Steele, V. E., Kelloff, G. J., Wilkinson, B. P., and Arnold, J. T. (1990) Cancer Res. 50, 2068-2074
42. Shklar, G., Schwartz, J., Grau, D., Trickler, D. P., and Wallace, K. D. (1980) Oral Surg. 50, 45-52
43. Medkova, M., and Cho, W. (1998) J. Biol. Chem. 273, 17544-17552
44. Cope, F. O., Howard, B. D., and Boutwell, R. K. (1986) Experientia (Basel) 42, 1023-1027
45. Sutton, R. B., and Sprang, S. R. (1998) Structure 6, 1395-1405
46. Gundimeda, U., Hara, S. K., Anderson, W. B., and Gopalakrishna, R. (1993) Arch. Biochem. Biophys. 300, 526-530
47. Cope, F. O. (1986) Cancer Lett. 30, 275-288

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
R. Alzamora, L. R. Brown, and B. J. Harvey
Direct Binding and Activation of Protein Kinase C Isoforms by Aldosterone and 17{beta}-Estradiol
Mol. Endocrinol., November 1, 2007; 21(11): 2637 - 2650.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S.-W. Kim, J. S. Hong, S.-H. Ryu, W.-C. Chung, J.-H. Yoon, and J. S. Koo
Regulation of Mucin Gene Expression by CREB via a Nonclassical Retinoic Acid Signaling Pathway
Mol. Cell. Biol., October 1, 2007; 27(19): 6933 - 6947.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Ertesvag, H.-C. Aasheim, S. Naderi, and H. K. Blomhoff
Vitamin A potentiates CpG-mediated memory B-cell proliferation and differentiation: involvement of early activation of p38MAPK
Blood, May 1, 2007; 109(9): 3865 - 3872.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. C. He, T.-C. Lu, M. Fleet, M. Sunamoto, M. Husain, W. Fang, S. Neves, Y. Chen, S. Shankland, R. Iyengar, et al.
Retinoic Acid Inhibits HIV-1-Induced Podocyte Proliferation through the cAMP Pathway
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 93 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
S. Aggarwal, S.-W. Kim, K. Cheon, F. H. Tabassam, J.-H. Yoon, and J. S. Koo
Nonclassical Action of Retinoic Acid on the Activation of the cAMP Response Element-binding Protein in Normal Human Bronchial Epithelial Cells
Mol. Biol. Cell, February 1, 2006; 17(2): 566 - 575.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. Pasquali, P. Chieffi, W. J Deery, G. Nicoletti, A. Bellastella, and A. A Sinisi
Differential effects of all-trans-retinoic acid (RA) on Erk1/2 phosphorylation and cAMP accumulation in normal and malignant human prostate epithelial cells: Erk1/2 inhibition restores RA-induced decrease of cell growth in malignant prostate cells
Eur. J. Endocrinol., April 1, 2005; 152(4): 663 - 669.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K.-W. Zhao, X. Li, Q. Zhao, Y. Huang, D. Li, Z.-G. Peng, W.-Z. Shen, J. Zhao, Q. Zhou, Z. Chen, et al.
Protein kinase C{delta} mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation
Blood, December 1, 2004; 104(12): 3731 - 3738.
[Abstract] [Full Text] [PDF]